Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4215-4221

  Jørgensen, Karin Meinike ^a   Wassermann, Tina ^a   Jensen, Peter Østrup ^c   Hengzuang, Wang ^c   Molin, Søren ^a   Høiby, Niels ^a,b,c   Ciofu, Oana ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS RESISTANCE; GENE MUTATION; GRAM NEGATIVE AEROBIC RODS AND COCCI; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MUTANT; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; WILD TYPE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CIPROFLOXACIN; DNA GYRASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS, DNA;

EID: 84882317549     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00493-13     Document Type: Article

References (30)

1. Yang L, Jelsbak L, Marvig RL, Damkiaer S, Workman CT, Rau MH, Hansen, SK, Folkesson A, Johansen HK, Ciofu O, Høiby N, Sommer MO, Molin S. 2011. Evolutionary dynamics of bacteria in a human host environment. Proc. Natl. Acad. Sci. U. S. A. 108:7481-7486.
2. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
3. Ciofu O, Riis B, Pressler T, Poulsen HE, Høiby N. 2005. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49:2276-2282.
4. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810.
5. Morero, NR, Monti MR, Argarana CE. 2011. Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators. Antimicrob. Agents Chemother. 55:3668-3676.
6. Wong A, Rodrigue N, Kassen R. 2012. Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genet. 8:e1002928. doi:10.1371/journal.pgen.1002928.
7. Wong A, Kassen R. 2011. Parallel evolution and local differentiation in quinolone resistance in Pseudomonas aeruginosa. Microbiology 157:937-944.
8. Moriarty TF, McElnay JC, Elborn JS, Tunney MM. 2007. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr. Pulmonol. 42:1008-1017.
9. Kohanski MA, Dwyer DJ, Collins JJ. 2010. How antibiotics kill bacteria: from targets to networks. Nat. Rev. Microbiol. 8:423-435.
10. Høiby N, Jarlov JO, Kemp M, Tvede M, Bangsborg JM, Kjerulf A, Pers C, Hansen H. 1997. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 349:167-169.
11. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. 2003. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 9:1415-1422.
12. Kohanski MA, DePristo MA, Collins JJ. 2010. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol. Cell 37:311-320.
13. Gullberg E, Cao S, Berg OG, Ilback C, Sandegren L, Hughes D, Andersson DI. 2011. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 7:e1002158. doi:10.1371/journal.ppat.1002158.
14. Elena SF, Lenski RE. 2003. Evolution experiments with microorganisms: the dynamics and genetic bases of adaptation. Nat. Rev. Genet. 4:457-469.
15. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N. 2009. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob. Agents Chemother. 53:2483-2491.
16. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N. 2010. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156:1108-1119.
17. Mandsberg LF, Macia MD, Bergmann KR, Christiansen LE, Alhede M, Kirkby N, Høiby N, Oliver A, Ciofu O. 2011. Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM). FEMS Microbiol. Lett. 324:28-37.
18. Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. 2011. Pharmacokinetics/ pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 55:4469-4474.
19. Chopra I, O'Neill AJ, Miller K. 2003. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6:137-145.
20. Oliver A, Levin BR, Juan C, Baquero F, Blazquez J. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233.
21. Macia MD, Borrell N, Segura M, Gomez C, Perez JL, Oliver A. 2006. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:975-983.
22. Nilsson AI, Kugelberg E, Berg OG, Andersson DI. 2004, Experimental adaptation of Salmonella typhimurium to mice. Genetics 168:1119-1130.
23. Mena A, Macia MD, Borrell N, Moya B, de Francisco T, Perez JL, Oliver A. 2007. Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. J. Bacteriol. 189:3665-3668.
24. Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, Tummler B, Cariani L, Conese M, Döring G, Bragonzi A. 2007. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153:1445-1454.
25. Barth AL, Pitt TL. 1996. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. J. Med. Microbiol. 45:110-119.
26. Kugelberg E, Lofmark S, Wretlind B, Andersson DI. 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 55:22-30.
27. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44: 710-712.
28. Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 25:290-295.
29. Akasaka T, Tanaka M, Yamaguchi A, Sato K. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45:2263-2268.
30. Macia MD, Perez JL, Molin S, Oliver A. 2011. Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. Antimicrob. Agents Chemother. 55:5230-5237.